Statins: Magic medicine is not a panacea
Statins, to be precise, HMG-CoA reductase preparations, have indeed set a brilliant record of drug sales in human history so far: Pfizer’s cumulative sales of atorvastatin have exceeded 160 billion U.S. dollars, Merck’s Simvastatin and Aspen Likang's rosuvastatin also reached 60 billion US dollars, plus lovastatin, pravastatin and fluvastatin, the cumulative sales of HMG-CoA reductase inhibitors have reached 300 billion US dollars . In addition to economic value, because of the emergence of statins, the mortality rate of human cardiovascular diseases can be greatly reduced.
But risk reduction is not foolproof. Although statin treatment can achieve the level of low-density lipoprotein cholesterol LDC-C in patients with hyperlipidemia and reduce the overall risk of cardiovascular disease by 25%-35%, there is still an average of up to 70%. % Of cardiovascular disease risk persists, so treatment of residual cardiovascular risk is urgent. A meta-analysis released in 2013 showed that for every 1mmol/L (88mg/dL) increase in triglyceride TG, the risk of cardiovascular death increased by 13%, and the risk of all-cause death increased by 12%. Therefore, in order to reduce the residual cardiovascular risk more significantly, in addition to low-density lipoprotein, it is necessary to reduce triglycerides (TG).
To reduce triglycerides, Vascepa relies on high-purity EPA to become a god
To use an analogy, LDL and triglycerides are more like the relationship between the driver and the passenger. Low-density lipoprotein is also a kind of fat. Its function is to transport triglycerides into cells. If there is no low-density lipoprotein, triglycerides cannot be transported into cells to be used. The dynamic balance of triglycerides and low-density lipoproteins ensures that triglycerides can be continuously transported to vascular endothelial cells for use, and when vascular endothelial cells are damaged, the blood triglycerides or low-density lipoproteins are too high , It will cause an excess of triglycerides in the cell. Excessive triglycerides can cause inflammation and degeneration of vascular endothelial cells, turning them into "porridge"-like substances, destroying the structure of blood vessels, forming atherosclerosis and plaques.
So how to effectively reduce triglycerides? This will return to the clinical trial involving 8,179 people mentioned in the opening paragraph. The experiment divided 8179 patients with long-term cardiovascular disease or diabetes and other risk factors who were taking statin treatment into two groups randomly, and received Vascepa (2g, twice a day) or placebo on the basis of statin treatment. The median follow-up time was 4.9 years. The main composite endpoint (five-point MACE) events included cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or unstable angina. Key secondary composite endpoints (three-point MACE) events include cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. The results showed that, compared with placebo, the TG level of Vascepa treatment group was significantly reduced. Vascepa can further reduce cardiovascular risk by 25% on the basis of 25%-35% of cardiovascular risk reduced by statin background treatment. In addition, Vascepa also reduced the risk of cardiovascular death, heart attack (fatal/non-fatal), and stroke (fatal/non-fatal) by 20%, 31%, and 28%, respectively.
You must ask, what kind of "fairy drug" is Vascepa? You may not believe it, Vascepa (IPE, Icosapent Ethyl, Eicosapentaenoic Acid) is a high-purity EPA (Eicosapentaenoic Acid) single-molecule prescription drug produced with patented technology. The U.S. Food and Drug Administration (FDA) has approved the combination of IPE and maximum tolerated statins to reduce elevated triglyceride (TG) levels (≥150 mg/dL) with confirmed cardiovascular disease, or diabetes and associated Adult patients with ≥2 cardiovascular disease risk factors are at risk of hospitalization for myocardial infarction, stroke, coronary revascularization, and unstable angina pectoris; and combined with diet therapy to reduce severe hypertriglyceridemia ( ≥500mg/dL) TG level in adult patients. Not long ago, the results of the Vascepa China Phase III study have also been announced: the effectiveness and safety of IPE in Chinese patients have been further confirmed.
Food and medicine are being promoted simultaneously, algae oil EPA is strong in the big health field
Speaking of this, the cutting-edge application of EPA in the pharmaceutical field can temporarily come to an end, and the application of EPA in the field of nutrition and food has just begun.
In the list of new food raw materials just approved in 2021, Pseudochlorococcum is on the list. This signifies that the plant-derived EPA is officially allowed to enter the Chinese food market. According to common sense, the force of medicines to foods makes the same raw material often need to go through a long evolutionary path from medicines to nutritional products to functional foods. However, it seems that the advancement of EPA in medicines, nutritional products and even foods is almost synchronized at the level of regulations and applications. This also conveys an important signal: As an important functional ingredient to reduce triglycerides and thereby reduce the risk of cardiovascular disease, EPA has not only gained recognition in the medical field, but will also release unlimited potential in the nutrition and food fields. Shenzhen Qianhai Xiaozao Technology Co., Ltd. (hereinafter referred to as Xiaozao Technology) is undoubtedly one of the first companies to realize this potential.
From "cultivating algae" to "using algae", this company wants to make all foods "get some algae™"
The predecessor of Chlorella Technology was Lyxia, which was established in 2012 in Delaware, USA. As a high-tech enterprise focusing on the R&D and commercial application of natural microalgae and its derivatives, its core products are Pure EPA microalgae oil, EPA microalgae blending oil, whole fat algae powder, defatted algae powder. Xiaozao Technology has an independent microalgae research and development laboratory and a professional microalgae technology research and development team in Shenzhen, and a world-class microalgae farming production base in Guangxi. It is currently the largest microalgae farming base in China, with a systematic end-to-end system. Production and processing technological process.
The first phase production base in Guangxi is responsible for downstream oil extraction production, covering an area of 87 acres, with oil extraction processing workshops, cold storage, warehouses and shaded rooms. The second phase of the breeding base is responsible for upstream breeding production. The planned area of the project is 3,200 mu, with a total investment of 350 million yuan. The first phase of 1,200 mu will be completed in June, including 141 large and small breeding ponds, as well as 1,370 square meters of centrifuge rooms and 2,859 square meters of office area. It produces 220 tons of concentrated algae pulp and 660 tons of algae powder.
It is particularly worth mentioning that since its establishment in 2016, Chlorella Technology has invented a number of microalgae cultivation and extraction technology patents, and successfully screened and cultivated microalgae containing only EPA and realized large-scale cultivation. It has achieved a breakthrough in EPA extraction technology, and can successfully extract high-purity EPA ethyl ester refined algae oil. The products are widely used in baking, vegetable meat, soft candy, protein bars, jelly, solid beverages, pasta products and other fields. It will not affect the appearance, color, and smell of the final product, making the product more in line with market consumption habits, and successfully subverting the previous consumer stereotype of the “unpalatable” algae oil, making the algae oil EPA can be used in the field of food, beverage and nutritional products. Achieve "application without boundaries."
Whether in the world or in China, cardiovascular diseases occupy the first cause of death among residents. In fact, medicine and evidence-based nutrition have long been agreed that it is entirely possible to prevent and assist treatment early through reasonable diet and nutritional intervention when abnormal blood lipids appear in the early stage. Algae oil EPA, as an effective ingredient endorsed in the medical field, will surely lead a new round of growth hotspots after breaking through the limitations of food applications, and let the food "Let Dian Algae™" inevitably set off a "green wave" in the big health field.
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Global food prices climb sharply in May
Dexin announces strategic investment in Swedencare as pet food prospects grow
Major sweetener supplier signs up with Finmayil for stevia extract
G20 countries have room for improvement in food sustainability
Compound condiment market size will cross the 200 billion threshold
Oral beauty consumption has great potential, can collagen tripeptide lead to a new round of accelerated growth?